Profile data is unavailable for this security.
About the company
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
- Revenue in USD (TTM)6.30bn
- Net income in USD501.00m
- Incorporated2020
- Employees10.00k
- LocationOrganon & Co30 Hudson Street, Fl 33JERSEY CITY 07302United StatesUSA
- Phone+1 (551) 430-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.organon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Inc | 250.04m | -4.99m | 1.71bn | 382.00 | -- | 36.28 | 124.69 | 6.82 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.78bn | 1.37k | -- | 1.35 | -- | 0.7393 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.79bn | 357.00 | 189.00 | 5.56 | 77.19 | 6.92 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.83bn | 897.00 | 49.98 | 3.62 | 14.04 | 2.21 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.88bn | 300.00 | 25.42 | 5.14 | 19.33 | 7.07 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.90bn | 325.00 | -- | 2.94 | -- | 36.54 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 1.96bn | 8.38k | -- | 0.4416 | 6.49 | 0.4587 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Phibro Animal Health Corp | 1.40bn | 67.82m | 2.03bn | 2.48k | 30.06 | 6.49 | 17.29 | 1.45 | 1.66 | 1.66 | 34.35 | 7.70 | 1.19 | 2.56 | 7.39 | 565,525.70 | 5.77 | 3.89 | 7.12 | 4.87 | 31.92 | 31.14 | 4.85 | 3.69 | 1.35 | 3.41 | 0.7045 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.10bn | 246.00 | 11.47 | 2.51 | 10.01 | 2.54 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Organon & Co | 6.30bn | 501.00m | 2.11bn | 10.00k | 4.21 | 2.32 | 2.50 | 0.3342 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 248.52m | -278.00k | 2.12bn | 188.00 | -- | 21.38 | 623.93 | 8.53 | -0.0055 | -0.0055 | 2.53 | 1.01 | 1.39 | 1.11 | 6.25 | 1,321,899.00 | -0.1554 | -42.00 | -0.2203 | -50.53 | 91.09 | -- | -0.1119 | -194.15 | 2.37 | -0.5126 | 0.2618 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Ultragenyx Pharmaceutical Inc | 630.60m | -579.83m | 2.30bn | 1.29k | -- | 250.50 | -- | 3.64 | -5.94 | -5.94 | 6.46 | 0.095 | 0.4622 | 2.02 | 6.13 | 487,324.60 | -42.50 | -33.04 | -55.49 | -38.84 | 84.69 | 91.29 | -91.95 | -127.45 | 1.74 | -17.52 | 0.9809 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
Data as of Feb 06 2026. Currency figures normalised to Organon & Co's reporting currency: US Dollar USD
41.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 34.77m | 13.38% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 27.75m | 10.68% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 9.34m | 3.59% |
| LSV Asset Managementas of 30 Sep 2025 | 7.83m | 3.01% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 6.70m | 2.58% |
| Geode Capital Management LLCas of 30 Sep 2025 | 4.82m | 1.85% |
| Millennium Management LLCas of 30 Sep 2025 | 4.53m | 1.74% |
| UBS Securities LLCas of 31 Dec 2025 | 4.19m | 1.61% |
| AQR Capital Management LLCas of 30 Sep 2025 | 4.18m | 1.61% |
| Gotham Asset Management LLCas of 30 Sep 2025 | 3.71m | 1.43% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
